Shenglian Gan

机构：Endocrine Society, The First People's Hospital of Changde · ORCID：0000-0003-3005-183X

发表论文 35 篇 · 总被引 801 次 · h-index 11

代表论文

• Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial (2023 · Diabetes Care · 被引 81)
• Efficacy and safety of GLP-1 analog ecnoglutide in adults with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 2 trial (2024 · Nature Communications · 被引 31)
• Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial (2023 · American Journal of Kidney Diseases · 被引 30)
• Berberine Ursodeoxycholate for the Treatment of Type 2 Diabetes (2025 · JAMA Network Open · 被引 29)
• Gamma-glutamyl transferase to high-density lipoprotein cholesterol ratio is a more powerful marker than TyG index for predicting metabolic syndrome in patients with type 2 diabetes mellitus (2023 · Frontiers in Endocrinology · 被引 21)
• Diabetes remission in drug‐naïve patients with type 2 diabetes after dorzagliatin treatment: A prospective cohort study (2023 · Diabetes Obesity and Metabolism · 被引 18)